Abstract
Porcine circovirus Type 2 (PCV2) is a primary etiological pathogen of post-weaning multi-systemic wasting syndrome (PMWS). The capsid protein of PCV2 is the crucial immunogenic protein which can induce antibody generation and immune responses. However, there is still a lack of efficient PCV2 vaccines with high immunogenicity. In the current study, we developed a novel engineered PCV2 capsid (∆1-41aa)-pFc fusion protein (PCFP), which comprised a truncated capsid protein of PCV2 and a porcine IgG Fc fragment, fused to the capsid protein of PCV2 at the C-terminus. We found that this novel fusion protein could auto-assemble into virus-like nanoparticles with an estimated mean diameter of 22.6 nm, characterized by transmission electron microscopy. Immunization of BALB/c mice with this fusion protein significantly increased the production levels of anti-PCV2-capsid protein antibody in serum. Besides, the virus-like nanoparticles, PCFP was demonstrated to induce efficient cellular immune responses in mice, as evident by the high specific T cell reactivity to the PCFP fusion protein and the high production of the immune cytokines IFN-γ and IL-10 in an ex vivo re-stimulation system. Collectively, these findings demonstrate that the PCV2 truncated capsid subunit Fc-fusion protein can induce both cellular and humoral immune responses, and it displays great application potential.
Highlights
Porcine circovirus Type 2 (PCV2), a small non-enveloped single-stranded circularDNA virus, is considered to be a critical pathogen of several porcine circovirus-associated diseases (PCVAD) [1,2,3]
To construct the expression vector of the pEM-PCV2 capsid (∆1-41aa)pFc fusion protein, the recombinant PCFP genes were synthesized based on the bias codon for mammalian cells and amplified by polymerase chain reaction (PCR) using a pair of oligonucleotide primers
PCV2 has been has been evolving into new subtypes from PCV2a, resulting in the failure of current evolving into new subtypes from PCV2a, resulting in the failure of current PCV2 vaccines
Summary
Porcine circovirus Type 2 (PCV2), a small non-enveloped single-stranded circular. DNA virus, is considered to be a critical pathogen of several porcine circovirus-associated diseases (PCVAD) [1,2,3]. PCV2 has evolved into a series of new subtypes, such as PCV2a, PCV2b, PCV2c, PCV2d and PCV2e, since 1998, when it was identified. PCV2d has replaced PCV2b as the predominant PCV2 genotype in prevalence and circulation in swine herds [4,5,6,7,8]. The high mutation frequency of PCV2 creates great challenges in vaccine research and development [9]. A strain of PCV2b 41513 with new mutations has already been isolated from a failed case of a commercial PCV2 vaccine
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.